Literature DB >> 5824076

Tissue iodoprotein formation during the peripheral metabolism of the thyroid hormones.

M I Surks, H L Schwartz, J H Oppenheimer.   

Abstract

The formation of tissue iodoproteins during the peripheral metabolism of the thyroid hormones was examined by determining the concentration of nonethanol-extractable (125)I (NE(125)I) in various tissues after the intravenous injection of 3,5,3'-triiodo-L-thyronine (T3-(125)I) and L-thyroxine-(125)I (T4-(125)I) in groups of rats with iodide-blocked thyroid glands. 3 days after T3-(125)I and 7 days after T4-(125)I injection the concentration of NE(125)I in the liver and kidney was 5-10 times greater than in plasma. Smaller but nonetheless significant concentrations of NE(125)I were demonstrated in skeletal and cardiac muscle. Hepatic subcellular fractionation studies revealed that the major portion of the liver NE(125)I was in the microsomal fraction. Lower concentrations of NE(125)I were present in the nuclear, mitochondrial, and soluble fractions. When similar studies were performed in groups of rats pretreated with phenobarbital, an increase in the metabolic clearance of T3-(125)I (30%) and T4-(125)I (100%) was observed along with a highly significant increase in the NE(125)I concentration of the liver and plasma. The increase in hepatic NE(125)I in these studies was primarily due to the microsomal component. Incubation of hepatic microsomes with T3-(125)I and T4-(125)I showed that NEI formation as well as deiodination appeared to obey simple Michaelis-Menten kinetics. Moreover, the maximal rate of both deiodination and NEI formation was increased when microsomes harvested from phenobarbital-treated rats were employed. These studies indicate that thyroid hormone metabolism results in the formation of structural and soluble tissue iodoproteins in addition to circulating iodoproteins. The rate of formation of these moieties in the liver and plasma appears to be related to the rate of hormone metabolism.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5824076      PMCID: PMC297470          DOI: 10.1172/JCI106183

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  [DEIODINATION IN VIVO OF H-3- AND I-125-3,5-THYROXIN].

Authors:  J NUNEZ; L RAPPAPORT; C JACQUEMIN; J ROCHE
Journal:  C R Seances Soc Biol Fil       Date:  1964

2.  Some notes on the exchange of iodine with thyroxine homologues.

Authors:  G I GLEASON
Journal:  J Biol Chem       Date:  1955-04       Impact factor: 5.157

3.  [On the intermediate products and mechanism of deiodination of thyroid hormones].

Authors:  C JACQUEMIN; J NUNEZ; J ROCHE
Journal:  Gen Comp Endocrinol       Date:  1963-06       Impact factor: 2.822

4.  The mechanism of protein iodination during the metabolism of thyroid hormones by peripheral tissues.

Authors:  V A GALTON; S H INGBAR
Journal:  Endocrinology       Date:  1961-07       Impact factor: 4.736

5.  An iodine compound associated with albumin in the plasma of thyrotoxic patients.

Authors:  C CAMERON; K FLETCHER
Journal:  Nature       Date:  1959-01-10       Impact factor: 49.962

6.  Transiodination of proteins during enzymic de-iodination of thyroxine.

Authors:  J R TATA
Journal:  Nature       Date:  1960-09-17       Impact factor: 49.962

7.  [Enzymatic deiodination of thyroxin and its derivatives. I. Purification and properties of thyroxin-deiodase from the rabbit muscle].

Authors:  S LISSITZKY; M ROQUES; M T BENEVENT
Journal:  Bull Soc Chim Biol (Paris)       Date:  1961

8.  Intracellular distribution of succinoxidase and cytochrome oxidase activities in normal mouse liver and in mouse hepatoma.

Authors:  W C SCHNEIDER; G H HOGEBOOM
Journal:  J Natl Cancer Inst       Date:  1950-02       Impact factor: 13.506

9.  Hepatic accumulation of 125I-thyroxine in the rat: augmentation by phenobarbital and chlordane.

Authors:  G Bernstein; S A Artz; J Hasen; J H Oppenheimer
Journal:  Endocrinology       Date:  1968-02       Impact factor: 4.736

10.  Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital.

Authors:  J H Oppenheimer; G Bernstein; M I Surks
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

View more
  5 in total

Review 1.  Mammalian peroxidasin (PXDN): From physiology to pathology.

Authors:  Guangjie Cheng; Ruizheng Shi
Journal:  Free Radic Biol Med       Date:  2022-02-24       Impact factor: 7.376

2.  Differences in primary cellular factors influencing the metabolism and distribution of 3,5,3'-L-triiodothyronine and L-thyroxine.

Authors:  J H Oppenheimer; H L Schwartz; H C Shapiro; G Bernstein; M I Surks
Journal:  J Clin Invest       Date:  1970-05       Impact factor: 14.808

3.  Thyroid dysfunction in chronic renal failure. A study of the pituitary-thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine.

Authors:  V S Lim; V S Fang; A I Katz; S Refetoff
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Ether link cleavage is the major pathway of iodothyronine metabolism in the phagocytosing human leukocyte and also occurs in vivo in the rat.

Authors:  A G Burger; D Engler; U Buergi; M Weissel; G Steiger; S H Ingbar; R E Rosin; B M Babior
Journal:  J Clin Invest       Date:  1983-04       Impact factor: 14.808

5.  Slow fractional removal of nonextractable iodine from rat tissue after injection of labeled L-thyroxine and 3,5,3'-triiodo-L-thyronine. A possible clue to the mechanism of initiation and persistence of hormonal action.

Authors:  J H Oppenheimer; M I Surks; H L Schwartz
Journal:  J Clin Invest       Date:  1972-11       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.